company background image
CRXT

Clarus Therapeutics Holdings NasdaqGM:CRXT Stock Report

Last Price

US$0.38

Market Cap

US$19.9m

7D

-2.1%

1Y

-96.2%

Updated

03 Jul, 2022

Data

Company Financials +
CRXT fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

CRXT Stock Overview

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States.

Clarus Therapeutics Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clarus Therapeutics Holdings
Historical stock prices
Current Share PriceUS$0.38
52 Week HighUS$31.24
52 Week LowUS$0.33
Beta0
1 Month Change-27.67%
3 Month Change-69.10%
1 Year Change-96.20%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.24%

Recent News & Updates

Shareholder Returns

CRXTUS PharmaceuticalsUS Market
7D-2.1%-0.7%-2.5%
1Y-96.2%10.4%-21.2%

Return vs Industry: CRXT underperformed the US Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: CRXT underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is CRXT's price volatile compared to industry and market?
CRXT volatility
CRXT Average Weekly Movement31.5%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: CRXT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 31% a week.

Volatility Over Time: CRXT's weekly volatility has increased from 23% to 31% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200316Robert Dudleyhttps://clarustherapeutics.com

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.

Clarus Therapeutics Holdings Fundamentals Summary

How do Clarus Therapeutics Holdings's earnings and revenue compare to its market cap?
CRXT fundamental statistics
Market CapUS$19.93m
Earnings (TTM)-US$35.71m
Revenue (TTM)US$15.64m

1.3x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRXT income statement (TTM)
RevenueUS$15.64m
Cost of RevenueUS$3.02m
Gross ProfitUS$12.62m
Other ExpensesUS$48.33m
Earnings-US$35.71m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.69
Gross Margin80.71%
Net Profit Margin-228.33%
Debt/Equity Ratio-126.8%

How did CRXT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CRXT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRXT?

Other financial metrics that can be useful for relative valuation.

CRXT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.2x
Enterprise Value/EBITDA-1.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CRXT's PS Ratio compare to its peers?

CRXT PS Ratio vs Peers
The above table shows the PS ratio for CRXT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average39.8x
ACER Acer Therapeutics
55.5x61.3%US$20.0m
TMBR Timber Pharmaceuticals
20.9xn/aUS$19.4m
CURR CURE Pharmaceutical Holding
3.3xn/aUS$20.6m
MJNE MJ Holdings
79.4xn/aUS$19.2m
CRXT Clarus Therapeutics Holdings
1.3x41.9%US$19.9m

Price-To-Sales vs Peers: CRXT is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (39.8x).


Price to Earnings Ratio vs Industry

How does CRXT's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: CRXT is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Pharmaceuticals industry average (4.1x)


Price to Sales Ratio vs Fair Ratio

What is CRXT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRXT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio29.1x

Price-To-Sales vs Fair Ratio: CRXT is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (29.1x).


Share Price vs Fair Value

What is the Fair Price of CRXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRXT ($0.38) is trading below our estimate of fair value ($48.45)

Significantly Below Fair Value: CRXT is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRXT's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Clarus Therapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


65.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRXT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRXT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRXT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRXT's revenue (41.9% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: CRXT's revenue (41.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CRXT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Clarus Therapeutics Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-71.5%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: CRXT is currently unprofitable.

Growing Profit Margin: CRXT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CRXT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CRXT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRXT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.9%).


Return on Equity

High ROE: CRXT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Clarus Therapeutics Holdings's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CRXT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CRXT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CRXT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CRXT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRXT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CRXT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.6% each year


Discover healthy companies

Dividend

What is Clarus Therapeutics Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRXT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRXT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRXT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRXT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Robert Dudley (67 yo)

18.42yrs

Tenure

US$2,475,346

Compensation

Dr. Robert E. Dudley, Ph.D. has been President, Chief Executive Officer and Director of Clarus Therapeutics Holdings, Inc. since September 9, 2021. Prior thereto, he served as Legacy Clarus’s Chief Executi...


CEO Compensation Analysis

Compensation vs Market: Robert's total compensation ($USD2.48M) is above average for companies of similar size in the US market ($USD799.15K).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CRXT's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: CRXT's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Clarus Therapeutics Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Clarus Therapeutics Holdings, Inc.
  • Ticker: CRXT
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$19.934m
  • Shares outstanding: 52.02m
  • Website: https://clarustherapeutics.com

Number of Employees


Location

  • Clarus Therapeutics Holdings, Inc.
  • 555 Skokie Boulevard
  • Suite 340
  • Northbrook
  • Illinois
  • 60062
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.